HDAC Inhibitors as Novel Anti-Cancer Therapeutics
The DOI matches its Crossref record.
Abstract
Malignant growth of cells is a condition characterized by unchecked cellular proliferation, genetic instability and epigenetic dysregulation. Up-regulated HDAC (Histone Deacetylase) enzyme activity is associated with a closed chromatin assembly and subsequent gene repression, forming a characteristic feature of malignantly transformed cells. Novel therapeutics are now targeting the zinc containing HDAC enzymes for treating various types of cancers. Recently, a spate of drugs acting via HDAC inhibition have been undergoing clinical trials and several patents present exciting molecules like PCI-24781 (Abexinostat), ITF- 2357 (Givinostat); MS-275 (Entinostat), MGCD 0103 (Mocetinostat), LBH-589 (Panobinostat), FK228 (Romidepsin), PXD-101 (Belinostat) and Valproic Acid to be used as alternatives or adjuvants to traditional chemotherapeutics. However, only three HDAC inhibitors have acquired FDA approval till date. Recently, PXD-101 obtained FDA approval for the treatment of Refractory or Relapsed Peripheral T cell lymphoma. The current article reviews patents that have introduced novel molecules that are HDAC isoform specific, superior to first generation HDAC inhibitors like SAHA (Suberoylanilide Hydroxamic Acid) and TSA (Trichostatin A) and can be modified structurally to reduce toxic side effects and increase specificity. These molecules can combine the best characteristics of an ideal HDAC inhibiting drug either as monotherapy or in combinatorial therapy for cancer treatment thus, indicating promise to be included in the next generation of target specific HDAC inhibiting drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Iron and cancer: recent insights
Manz, D. H., Blanchette, N. L., Paul, B. T., Torti, F. M., & Torti, S. V. (2016) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.13008 · Cited by 507
Safety and tolerability of histone deacetylase (HDAC) inhibitors in oncology
Shah, R. R. (2019) · Drug Safety · doi:10.1007/s40264-018-0773-9 · Cited by 197
Dichotomous engagement of HDAC3 activity governs inflammatory responses
Nguyen, H. C. B., Adlanmerini, M., Hauck, A. K., & Lazar, M. A. (2020) · Nature · doi:10.1038/s41586-020-2576-2 · Cited by 150
Mani, C., Tripathi, K., Luan, S., Clark, D. W., Andrews, J. F., Vindigni, A., Thomas, G., & Palle, K. (2020) · Oncogene · doi:10.1038/s41388-020-1167-x · Cited by 27
“Owing to their importance in cancer, several HDAC inhibitors have been approved for cancer treatment [14].”
Background
Metadata
- Authors
- Souza, C., & Chatterji, B.
- Venue
- Recent Patents on Anti-Cancer Drug Discovery
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2015-05-08
- Volume
- 10
- Issue
- 2
- Pages
- 145-162
- ISSN
- 1574-8928 (ISSN-L)
- OpenAlex
- W66671524
- Cited by
- 123
- References
- 0
- FWCI
- 5.15
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HDAC Inhibitors as Novel Anti-Cancer Therapeutics. https://app.cochat.ai/papers/10.2174/1574892810666150317144511
- The paper
- Souza, C., & Chatterji, B. (2015). HDAC Inhibitors as Novel Anti-Cancer Therapeutics. Recent Patents on Anti-Cancer Drug Discovery. https://doi.org/10.2174/1574892810666150317144511
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.